Jonathan M. Pratt became QIAGEN N.V.’s chief executive officer on September 1, 2026, replacing Thierry Bernard, who also left the Managing Board. Investors retain the company’s reaffirmed third-quarter and full-year 2026 outlook, while QIAGEN continues a strategic review and plans to propose Pratt as a Managing Director for Shareholder approval.
Key Highlights
- Thierry Bernard stepped down from QIAGEN’s Managing Board when Pratt assumed the CEO position.
- Jonathan M. Pratt became QIAGEN’s chief executive officer effective September 1, 2026.
- Thierry Bernard stepped down as CEO and from the Managing Board on September 1, 2026.
- QIAGEN reaffirmed its third-quarter and full-year 2026 outlook as its strategic review continues.
QIAGEN N.V. (NYSE: QGEN) appointed Jonathan M. Pratt as chief executive officer effective September 1, 2026, succeeding Thierry Bernard. Bernard also stepped down from the Managing Board on that date, while QIAGEN reaffirmed its third-quarter and full-year 2026 outlook.
Pratt Takes Over
as CEO Pratt brings more than 25 years of Leadership experience across life sciences, laboratory technologies and healthcare. His previous roles included chief executive officer of Filtration Group, senior vice president of the Waters Division at Waters Corporation (NYSE: WAT), and president of Beckman Coulter Life Sciences. He also held senior leadership positions at Pall Corporation. Bernard will support the leadership handover through the transition.
Outlook Reaffirmed
as Strategic Review Continues QIAGEN reaffirmed its outlook for the third quarter and full year of 2026. The company said it remains focused on profitable growth, operating efficiency and directing Capital toward the highest-return opportunities. The Supervisory Board is continuing its strategic review with independent financial and legal advisers.
FAQs
Q: Who became QIAGEN’s CEO in September 2026?
A: Jonathan M. Pratt became QIAGEN N.V.’s chief executive officer effective September 1, 2026. Thierry Bernard stepped down as CEO and from the Managing Board.
Q: What is QIAGEN’s 2026 outlook after the CEO change?
A: QIAGEN reaffirmed its outlook for the third quarter and full-year 2026. The company also said its strategic review remains ongoing.
Q: Will Jonathan Pratt join QIAGEN’s Managing Board?
A: It only says he became chief executive officer effective September 1, 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.